Skip to main content

Table 1 Clinical features and survival of study participants (N = 115)

From: Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma

Clinical features

N (%)

Survival

1 yr.(%)

2 yrs. (%)

p

Gender

 Male

88 (76.52)

63.67

38.98

 

 Female

27 (23.48)

62.96

57.89

0.523

Age (y.o)

 <60

37 (32.17)

56.76

29.63

 

 ≧60

78 (74.26)

66.67

45.28

0.207

ECOG

 0

49 (42.61)

75.51

54.29

 

 1

53 (46.09)

58.49

36.36

 

 2

13 (11.3)

46.15

20

0.118

Child-Pugh score

 A

104 (90.43)

68.27

47.14

 

 B

11 (9.57)

27.27

12.5

<0.001

AJCC stage (7th)

 I

21 (18.26)

85.71

78.57

 

 II

18 (15.65)

72.22

60

 

 IIIA

26 (22.61)

69.23

40

 

 IIIB

27 (23.48)

37.03

11.11

 

 IIIC

3 (2.61)

100

0

 

 IV

20 (17.39)

55

37.5

0.001

BCLC

 A

12 (10.44)

83.33

75

 

 B

23 (20)

86.26

56.25

 

 C

80 (69.56)

55

31.48

0.080

Tumor type

 Solitary

38 (33.04)

81.58

62.5

 

 Multiple

69 (60)

56.52

31.25

 

 Diffuse

8 (6.96)

37.5

33.33

<0.001

Tumor site

 Right

91 (79.13)

64.83

42.86

 

 Left

14 (13.04)

53.33

38.46

 

 Bilateral

10 (8.7)

60

0

0.506

Max. tumor diameter (cm)

 ≦4

40 (34.78)

75

55.17

 

 > 4-9

47 (40.87)

68.82

36.67

 

 ≧10

28 (23.48)

48.15

26.32

0.187

Portal vein tumor thrombosis

 Yes

34 (29.56)

35.29

12

 

 No

81 (70.43)

75.31

53.7

<0.001

Hepatitis virus

 B

59 (51.3)

66.1

36.58

 

 C

42 (36.52)

59.52

46.43

 

 Non B non C

11 (9.57)

81.82

77.78

 

 B + C

3 (2.61)

66.67

0

0.576

AFP Level (ng/ml)

 ≦20

41 (34.78)

82.93

62.5

 

 > 20-400

31 (27.84)

51.61

17.65

 

 ≧400

43 (37.39)

53.49

34.48

0.013

Biochemical changes

Albumin (g/dl) [N = 109]

 <3.5

26 (23.85)

46.15

31.81

 

 ≥3.5

83 (76.15)

67.47

44.64

0.027

Alkaline Phosphatase (IU/L) [N = 104]

 ≧129

37 (35.58)

59.45

42.57

 

 <129

67 (64.42)

64.18

36.95

0.893

Platelet (10^3/uL) [N = 109]

 <150

52 (47.71)

63.46

35

 

 ≧150

57 (52.29)

68.42

48.65

0.291

BED

 ≦72 Gy10

65 (56.52)

56.92

28.2

 

 73-88 Gy10

8 (6.96)

62.5

28.57

 

 ≧89 Gy10

42 (36.52)

76.19

56.25

0.038

Previous treatment

 Yes

52 (45.22)

50

37.14

 

 No

63 9(54.78)

55.56

43.18

0.584

  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, AJCC American Joint Cancer Conference, BCLC Barcelona Clinic Liver Cancer Stage, AFP Alpha-Feto Protein, BED Biological Effective Dose